

Listing of Claims

1. (Currently amended) A method for ~~treating~~ reducing inflammation in an animal having inflammation ~~caused by one or more of immune mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis,~~ comprising administering to the animal an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, wherein the mycobacterial deoxyribonucleic acid is preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.

2. (Cancel)

3-10. Previously cancelled

11. (Original) The method of Claim 1, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

12. (Cancel)

13. (Original) The method of Claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

14. (Cancel)

15. (Previously Cancelled)

16. (Currently amended) A method for ~~treating~~ reducing inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to ~~treat~~ reduce the inflammation.

17. (Cancel)

18. (Original) The method of Claim 16, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

19. (Cancel)

20. (Original) The method of Claim 16, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

21-23. (Cancel)

24. (Previously Presented) The method of Claim 1, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

25. (Previously Presented) The method of Claim 2, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

26. (Cancel)

27. (Cancel)

28. (New) The method of Claim 1, wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis or cystitis.

29. (New) The method of Claim 1, wherein the animal has osteoarthritis.

30. (New) The method of Claim 1, wherein the animal has colitis.

31. (New) The method of Claim 1, wherein the mycobacterium is selected from the group consisting of *M. vaccae*, *M. chelonae*, *M. smegmatis*, *M. terrae*, *M. duvalii*, *M. tuberculosis*, *M. bovis* BCG, *M. avium*, *M. Szulgai*, *M. scrofulaceum*, *M. xenopi*, *M. kansaii*, *M. gastr*, *M. fortuitous*, or *M. asiaticum*.

32. (New) The method of Claim 16, wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis.

33. (New) The method of Claim 16, wherein the animal has osteoarthritis.

34. (New) The method of Claim 16, wherein the animal has colitis.

35. (New) A method for inducing IL-10 production in an animal comprising administering to the animal an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to induce IL-10 production.

36. (New) The method of Claim 35, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
37. (New) The method of Claim 35, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.
38. (New) The method of Claim 35, wherein the mycobacterium is selected from the group consisting of *M. vaccae*, *M. chelonae*, *M. smegmatis*, *M. terrae*, *M. duvalii*, *M. tuberculosis*, *M. bovis* BCG, *M. avium*, *M. Szulgai*, *M. scrofulaceum*, *M. xenopi*, *M. kansaii*, *M. gastr*, *M. fortuitious*, or *M. asiaticum*.
39. (New) A method for inducing IL-10 production in an animal, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce IL-10 production.
40. (New) The method of Claim 39, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
41. (New) The method of Claim 39, wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, and cystitis.
42. (New) The method of Claim 22, wherein the mycobacterium is selected from the group consisting of *M. vaccae*, *M. chelonae*, *M. smegmatis*, *M. terrae*, *M. duvalii*, *M. tuberculosis*, *M. bovis* BCG, *M. avium*, *M. Szulgai*, *M. scrofulaceum*, *M. xenopi*, *M. kansaii*, *M. gastr*, *M. fortuitious*, or *M. asiaticum*.